These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 28376711)

  • 41. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
    Jeong SC; Aikata H; Katamura Y; Azakami T; Kawaoka T; Saneto H; Uka K; Mori N; Takaki S; Kodama H; Waki K; Imamura M; Shirakawa H; Kawakami Y; Takahashi S; Chayama K
    World J Gastroenterol; 2007 Oct; 13(40):5343-50. PubMed ID: 17879404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
    Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    Teng W; Hsieh YC; Lui KW; Chen WT; Hung CF; Huang CH; Chen YC; Jeng WJ; Lin CC; Lin CY; Lin SM; Sheen IS
    J Viral Hepat; 2017 Dec; 24(12):1160-1167. PubMed ID: 28643457
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Direct-acting antiviral treatment for patients with hepatocellular carcinoma.
    Kushner T; Dieterich D; Saberi B
    Curr Opin Gastroenterol; 2018 May; 34(3):132-139. PubMed ID: 29517502
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.
    Kanwal F; Kramer J; Asch SM; Chayanupatkul M; Cao Y; El-Serag HB
    Gastroenterology; 2017 Oct; 153(4):996-1005.e1. PubMed ID: 28642197
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
    Gonzalez HC; Gordon SC
    Gastroenterol Clin North Am; 2020 Jun; 49(2):301-314. PubMed ID: 32389364
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dynamic Evaluation of Liver Fibrosis to Assess the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis C Who Achieved Sustained Virologic Response.
    Toyoda H; Tada T; Yasuda S; Mizuno K; Ito T; Kumada T
    Clin Infect Dis; 2020 Mar; 70(6):1208-1214. PubMed ID: 31056696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.
    He S; Lockart I; Alavi M; Danta M; Hajarizadeh B; Dore GJ
    Aliment Pharmacol Ther; 2020 Jan; 51(1):34-52. PubMed ID: 31808566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dynamic noninvasive markers predict hepatocellular carcinoma in chronic hepatitis C patients without sustained virological response after interferon-based therapy: Prioritize who needs urgent direct-acting antiviral agents.
    Huang CM; Hu TH; Chang KC; Tseng PL; Lu SN; Chen CH; Wang JH; Lee CM; Tsai MC; Lin MT; Yen YH; Hung CH; Cho CL; Wu CK
    Medicine (Baltimore); 2017 Nov; 96(46):e8696. PubMed ID: 29145306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more.
    Pearlman BL; Traub N
    Clin Infect Dis; 2011 Apr; 52(7):889-900. PubMed ID: 21427396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
    Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
    J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis.
    Huang P; Liu M; Zang F; Yao Y; Yue M; Wang J; Fan H; Zhuo L; Wu J; Xia X; Feng Y; Yu R
    Carcinogenesis; 2018 Dec; 39(12):1497-1505. PubMed ID: 30602007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.
    Shirabe K; Sugimachi K; Harada N; Kayashima H; Maeda T; Tsujita E; Minagawa R; Kajiyama K; Yoshiya S; Maehara Y
    Anticancer Res; 2015 Dec; 35(12):6963-9. PubMed ID: 26637923
    [TBL] [Abstract][Full Text] [Related]  

  • 55. What Are the Benefits of a Sustained Virologic Response to Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection?
    Ioannou GN; Feld JJ
    Gastroenterology; 2019 Jan; 156(2):446-460.e2. PubMed ID: 30367836
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation.
    Zanaga LP; Vigani AG; Angerami RN; Giorgetti A; Escanhoela CA; Ataíde EC; Boin IF; Stucchi RS
    Braz J Med Biol Res; 2017 Jan; 50(1):e5540. PubMed ID: 28076451
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy.
    Omata M; Yoshida H; Shiratori Y
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S141-3. PubMed ID: 16234063
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liver stiffness-based score in hepatoma risk assessment for chronic hepatitis C patients after successful antiviral therapy.
    Wang JH; Yen YH; Yao CC; Hung CH; Chen CH; Hu TH; Lee CM; Lu SN
    Liver Int; 2016 Dec; 36(12):1793-1799. PubMed ID: 27254286
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders.
    Imai Y; Tamura S; Tanaka H; Hiramatsu N; Kiso S; Doi Y; Inada M; Nagase T; Kitada T; Imanaka K; Fukuda K; Takehara T; Kasahara A; Hayashi N
    J Viral Hepat; 2010 Mar; 17(3):185-91. PubMed ID: 19709362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achieving sustained virological response: what's the impact on further hepatitis C virus-related disease?
    van der Meer AJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):559-66. PubMed ID: 25579804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.